Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs - A meta-analysis

被引:115
作者
Kemmler, G
Hummer, M
Widschwendter, C
Fleischhacher, W
机构
[1] Innsbruck Univ Clin, Dept Gen Psychiat, A-6020 Innsbruck, Austria
[2] Innsbruck Univ Clin, Dept Biol Psychiat, A-6020 Innsbruck, Austria
关键词
D O I
10.1001/archpsyc.62.12.1305
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Context: Dropout rates in randomized clinical trials of antipsychotic drugs have consistently been reported to be high, and the use of a placebo-controlled design is hypothesized to be one of the reasons for this. Objective: To investigate this hypothesis in a meta-analysis of available data from pertinent clinical trials. Data Sources: Comprehensive search of PubMed- and MEDLINE-listed journals. Study Selection: Double-blind randomized controlled clinical trials of the second-generation antipsychotics risperidone, olanzapine, quetiapine, amisulpride, ziprasidone, and aripiprazole meeting the following criteria: unselected patient population with a diagnosis of schizophrenia or schizoaffective disorder, change in psychopathologic symptoms as the primary end point, and trial duration of 12 weeks or less. Data Extraction: Sample size, mean age, baseline disease severity, dropout rate, trial design, trial duration, and publication year. Data Synthesis: Thirty-one trials meeting the inclusion criteria were found, comprising 10 058 subjects. Weighted mean dropout rates in the active treatment arms were significantly higher in placebo-controlled trials (PCTs) than in active-control trials: 48.1% (PCTs) vs 28.3% (active-control trials) for second-generation antipsychotics (odds ratio, 2.34; 95% confidence interval, 1.58-3.47) and 55.4% (PCTs) vs 37.2% (active-control trials) for classical antipsychotics (odds ratio, 2. 10; 95% confidence interval, 1.29-3.40). Within PCTs, attrition rates were significantly higher in the placebo arms than with second-generation antipsychotics (60.2% vs 48.1%; odds ratio, 1.63; 95% confidence interval, 1.37-1.94). Within the subset of trials in which both second-generation and classical antipsychotics were used, dropout rates were significantly higher with classical antipsychotics. Conclusions: Use of a placebo-controlled design had a major effect on the dropout rates observed. Because high dropout rates affect the generalizability of such studies, it is suggested that, in addition to the PCTs, studies with alternative designs need to be considered when evaluating an antipsychotic's clinical profile.
引用
收藏
页码:1305 / 1312
页数:8
相关论文
共 61 条
  • [21] Feasibility of placebo-controlled clinical trials of antipsychotic compounds in Europe
    Fleischhacker, WW
    Burns, T
    [J]. PSYCHOPHARMACOLOGY, 2002, 162 (01) : 82 - 84
  • [22] FLEISCHHACKER WW, IN PRESS SCHIZOPHR R
  • [23] Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis
    Geddes, J
    Freemantle, N
    Harrison, P
    Bebbington, P
    [J]. BRITISH MEDICAL JOURNAL, 2000, 321 (7273): : 1371 - 1376
  • [24] An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder
    Goff, DC
    Posever, T
    Herz, L
    Simmons, J
    Kletti, N
    Lapierre, K
    Wilner, KD
    Law, CG
    Ko, GN
    [J]. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1998, 18 (04) : 296 - 304
  • [25] RISPERIDONE VERSUS PERPHENAZINE IN THE TREATMENT OF CHRONIC-SCHIZOPHRENIC PATIENTS WITH ACUTE EXACERBATIONS
    HOYBERG, OJ
    FENSBO, C
    REMVIG, J
    LINGJAERDE, O
    SLOTHNIELSEN, M
    SALVESEN, I
    [J]. ACTA PSYCHIATRICA SCANDINAVICA, 1993, 88 (06) : 395 - 402
  • [26] Attitudes of patients with schizophrenia toward placebo-controlled clinical trials
    Hummer, M
    Holzmeister, R
    Kemmler, G
    Eder, U
    Hofer, A
    Kurzthaler, I
    Oehl, M
    Weiss, E
    Fleischhacker, WW
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2003, 64 (03) : 277 - 281
  • [27] RISPERIDONE VERSUS ZUCLOPENTHIXOL IN THE TREATMENT OF ACUTE SCHIZOPHRENIC EPISODES - A DOUBLE-BLIND PARALLEL-GROUP TRIAL
    HUTTUNEN, MO
    PIEPPONEN, T
    RANTANEN, H
    LARMO, I
    NYHOLM, R
    RAITASUO, V
    [J]. ACTA PSYCHIATRICA SCANDINAVICA, 1995, 91 (04) : 271 - 277
  • [28] Hwang TJ, 2003, J FORMOS MED ASSOC, V102, P30
  • [29] Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: Results of the Japan multicenter, double-blind olanzapine trial
    Ishigooka, J
    Inada, T
    Miura, S
    [J]. PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2001, 55 (04) : 403 - 414
  • [30] Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder
    Kane, JM
    Carson, WH
    Saha, AR
    McQuade, RD
    Ingenito, GG
    Zimbroff, DL
    Ali, MW
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2002, 63 (09) : 763 - 771